

# **Hemispherx Biopharma Invited to Present New Anti HIV Data at DART Conference: Phase IIB Clinical Trials of Strategic Treatment Intervention**

Release: 11/25/2002

**Major Drug Development in Antiretroviral Research (DART) Conference 2002 in Naples, Florida, Tuesday, December 17**

**Philadelphia, PA, Monday, November 25, 2002:** Hemispherx Biopharma, Inc. (Amex: HEB) announced today that it will present expanded new interim data from the Phase IIB HIV Clinical Trials of its RNA-based Ampligen® in Structured Treatment Interruption (STI), at the Drug Development in Antiretroviral Research (DART) Conference December 15-19. Hemispherx Clinical Director David Strayer, M.D., will present on December 17 in Naples, Florida. The conference assembles leading AIDS researchers worldwide at its annual meeting.

Hemispherx focuses on the development of nucleic acids to enhance anti-viral defense systems. It is the leading company in the experimental-stage development of immune-based therapies primarily addressing the diseases of HIV/AIDS and Chronic Fatigue Syndrome. HIV DART is one of the leading international conferences focusing on antiretroviral research and HIV.

The article, "A Phase IIB Prospective, Randomized, Controlled Study Evaluating the Immunomodulatory Role of Poly I:Poly C12U Against HIV During STI," will discuss new interim results from the ongoing study in eight sites around the country. Earlier peer review data suggested a median of more than 27 weeks off HIV therapy medications without significant viral rebound, compared with seven weeks in patients undergoing STI without Ampligen®. Without interrupted treatment, HIV medications may lead to multi-drug resistance due to viral mutations as well as unacceptable long-term toxicity.

Hemispherx Biopharma, based in Philadelphia, is a bio-pharmaceutical company engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including, HIV, CFS and Hepatitis. Its platform technology includes large and small agent components for potential treatment of various chronic viral infections. For more information visit the company's Web site at <https://www.hemispherx.net>.

Contact(s):

Hemispherx Biopharma, Inc., Investor Relations  
(215) 988-1712, Fax: (215) 988-1554

Dianne Will, Investor Relations  
(518) 398-6222, Fax: (518) 398-6223

Wesley Stanton, MRB Institutional Investors, MRB  
(212) 495-0200 ext. 11, Fax: (212) 495-0746

Media:

Robin Wagge, Rubenstein Associates, Inc.  
(212) 843-9006, [rwagge@rubenstein.com](mailto:rwagge@rubenstein.com)

HEB's Web Site: [www.hemispherx.net](http://www.hemispherx.net)

Information contained in this news release other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risk of competition, changing market conditions, change in laws and regulations affecting these industries

and numerous other factors discussed in this release and in the Company's filings with the Securities and Exchange Commission. Accordingly, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update these forward-looking statements.